Page
%P
![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Open AccessHairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms
-
Article
Comparison of karyotype scoring guidelines for evaluating karyotype complexity in chronic lymphocytic leukemia
-
Article
Correction: Evaluation of bleeding events in patients receiving acalabrutinib therapy
-
Article
Evaluation of bleeding events in patients receiving acalabrutinib therapy
-
Article
Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib
-
Article
Second cancer incidence in CLL patients receiving BTK inhibitors
Chronic lymphocytic leukemia (CLL) is associated with perturbed immune function and increased risk for second primary malignancies (SPM). Ibrutinib and acalabrutinib (BTKi) are effective therapies for CLL resu...
-
Article
Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies